USAQ
QHSLab, Inc.Company with tickers: USAQ
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $728,685 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Cost of Revenue | $257,882 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Gross Profit | $470,803 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Expenses | $565,183 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $120,909 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-94,380 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-103,906 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $0.00 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $0.00 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Integrated Service Program | $270,022 | $643,211 | $1,121,134 |
| Allergy Diagnostic Kit Sales | $666,600 | $832,987 | $823,108 |
| Immunotherapy Treatment Sales | $363,184 | $409,319 | $487,762 |
| Clinical Study Revenue | — | $133,650 | $133,650 |
| Subscription Revenue | $72,200 | $54,523 | $43,731 |
| Shipping And Handling | $32,339 | $35,892 | $41,670 |
| Training And Other Revenue | $4,650 | $22,344 | $40,686 |